Neuroendocrine prostate cancer (NEPC)-associated <i>CEP55</i> promotes cisplatin resistance in prostate cancer by regulating CDK1 phosphorylation.

ABSTRACT: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of castration-resistant prostate cancer (CRPC) that is typically resistant to nearly all current therapies. In this study, single-cell RNA sequencing (scRNA-seq) and dataset analyses identified Centrosomal Protein 55 (CEP55) as a critical factor in the transformation from hormone-sensitive prostate cancer (HSPC) to CRPC and, ultimately to, NEPC. Subsequent bioinformatics analyses and validation with clinical samples demonstrated that CEP55 is significantly upregulated in NEPC tissues compared to HSPC and CRPC. Furthermore, while CEP55 show no significant association with the immune microenvironment or cancer-associated fibroblasts (CAFs), our findings indicate that it directly mediates the plasticity of pro

SUBMITTER: Lai Z 

PROVIDER: S-EPMC12704070 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature